logo-loader
viewG Medical Innovations Holdings Ltd

G Medical Innovations eyes significant revenue growth in the UK and US

Snapshot

The company has seven accounts in the UK that have successfully trialled its health monitoring solution, Patch.

hospital

Quick facts: G Medical Innovations Holdings Ltd

Price: 0.098 AUD

ASX:GMV
Market: ASX
Market Cap: $40.07 m
Follow

G Medical Innovations Holdings Ltd (ASX:GMV) established its UK headquarters last quarter and successfully completed the pilot programs for its CE approved health monitoring solution, Patch.

The UK market for G Medical comprises of the NHS (both primary and secondary), private hospital groups, nursing and aged care facilities as well as other market participants.

UK's healthcare system and reimbursement regime are very complimentary and compatible with G Medical’s business model and services, and is an important territory for deployment, given both the Prizma and the Patch are already regulatory approved for use within the UK.

 

Reimbursement rates for typical services in the UK range from ~£500 and £700, varying from site to site and depending upon the insurance company’s reimbursement rates.

Notably, G Medical has 7 accounts that have successfully trialled the Patch, with the view to forming definitive arrangements.

The typical value of each of these accounts is ~£256,000 per annum.

IDTF operations in the USA

G Medical Diagnostic Services Inc’s (GMEDx) Independent Diagnostic Testing Facility (IDTF) operations has seen consistent month on month new patient enrolment in the US.

As part of GMEDx’ growth strategy, the division will gradually increase its sales force to provide for continued increase in patient enrollments within the market, as well to push Prizma from POC to full commercialisation.

 

The revenue profile GMEDx has grown significantly in the short time since CardioStaff and Telerhythmic were acquired and amalgamated into GMEDx, with the revenue growth having increased ~200% from ~US$0.98 million for H1 2018 to ~US$3 million for H1 2019.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of G Medical Innovations Holdings Ltd named herein, including the promotion by the Company of G Medical Innovations Holdings Ltd in any Content on...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Australian e-health company G Medical Innovations eyes Nasdaq listing

G Medical Innovations Holdings Ltd (ASX:GMV) CEO Yacov Geva sits down with Proactive Investors' Christine Corrado in New York to update investors on the mobile and e-health company's move to list on the Nasdaq. Geva says the company, which specializes in software and devices that aim to...

on 16/10/18

2 min read